GAM
IOVA icon

GQ Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

GQ Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$81K Buy
+2,695
New +$71.4K 0.15% 39

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

GQ Asset Management's IOVA Position: Q1 2020 in Review

GQ Asset Management opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2020: 2,695 shares worth $81K. The stake represents 0.15% of the portfolio and ranks #39 among its holdings.

219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

  • GQ Asset Management held 2,695 shares of Iovance Biotherapeutics worth $81K as of Q1 2020.
  • Iovance Biotherapeutics was a new GQ Asset Management position in Q1 2020.
  • Iovance Biotherapeutics made up 0.15% of GQ Asset Management's portfolio in Q1 2020, its #39 holding.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on GQ Asset Management's 13F filing for Q1 2020, filed 8 May 2020.